Last updated on March 2018

A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)


Brief description of study

This is a non-randomized, open-label, Phase Ib study of atezolizumab in combination with immunomodulatory agents for the treatment of participants with AML (relapsed/refractory and treatment-naive, elderly participants unfit for induction chemotherapy). The study has been designed with the intent, over time, to study multiple combinations of atezolizumab with different immunomodulatory agents in participants with AML. The study will begin with the evaluation of the combination of atezolizumab and guadecitabine (Arm A). In the future, additional arms may be added.

Clinical Study Identifier: NCT02892318

Contact Investigators or Research Sites near you

Start Over

City of Hope
Duarte, CA United States

Yale University
New Haven, CT United States

The NewYork-Presbyterian Hospital Columbia University Medical Center
New York, NY United States

Memorial Sloan Kettering Cancer Center
New York, NY United States

Levine Cancer Institute
Charlotte, NC United States

Temple University Hospital
Philadelphia, PA United States

Huntsman Cancer Institute
Salt Lake City, UT United States

The University of Wisconsin School of Medicine and Public Health
Madison, WI United States